Capitol Federal Financial is enhancing its profitability by moving from residential mortgages to higher-yield commercial loans. The bank's net interest margin increased to 2.31%, with a Q3 net profit of $23.6 million and earnings per share of $0.19. Although profitability still trails some peers, the stock trades at a mixed valuation, reflecting cautious optimism among investors. Risks include concentration in commercial real estate and potential credit quality issues, but improving margins and shareholder returns support a positive outlook.
Capitol Federal Financial's net interest margin rose to 2.31%, reflecting its shift toward higher-yield commercial loans. For readers following the financial sector, here is Pluang's market snapshot as of Oct 06, 2026 18:43 WIB: out of 85 priced US financial stocks, 70 rose and 10 fell. Notable movers include Barclays PLC (BCS) at USD 23.91 with a 1-day change of +1.36% and 100% sell order activity, Aegon Ltd. (AEG) at USD 8.60 with a 1-day change of +1.30% and 100% buy order activity, and Deutsche Bank AG (DB) at USD 35.42 with a 1-day change of +1.29% and 100% buy order activity.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Allstate has opened the Auto Lab at its Claims University in Dallas, a hands-on training center where claims adjusters work with 22 vehicles and four motorcycles, including electric, hybrid, and gas-powered models. The lab uses real damaged vehicles ...
1911 Gold Corp reported high-grade gold drill results extending the 710-711 and 007 zones at its True North Gold Project in Manitoba. Highlights include 32.40 g/t gold over 1.10 meters from underground drilling 720 meters below surface. The results s...
Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERE...
Apple's stock surged nearly 1200% over the last decade, turning $10,000 into about $129,600. However, with its market cap near $5 trillion, future growth is expected to slow. Models project a $10,000 investment today could grow to around $16,494 by 2...
